Grifols, S.A. Operating Income 2011-2026 | GRFS

Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.

Formula

Operating profit = Revenue – Operating expenses

Features of the metric

Evaluates business efficiency
Shows how well the company controls its production and administrative costs.
Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies.
Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.

If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.

Annual Operating Income Grifols, S.A.

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	-	-	595 M	996 M	1.13 B	994 M	1 B	939 M	970 M	-	-	-	-

All numbers in EUR currency

Indicator range from annual reports

Maximum	Minimum	Average
1.13 B	595 M	947 M

Operating Income of other stocks in the Biotechnology industry

Issuer	Operating Income	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	-508 M	-	2.43 %	$ 254 M	Germany
ARCA biopharma ABIO	-88.1 M	-	1052.0 %	$ 415 M	USA
Aeterna Zentaris AEZS	-8.67 M	-	5.93 %	$ 314 M	Canada
Akero Therapeutics AKRO	-285 M	-	-	$ 3.67 B	USA
Akouos AKUS	-86.8 M	-	0.23 %	$ 488 M	USA
Genfit SA GNFT	31.8 M	-	2.54 %	$ 160 B	France
Albireo Pharma ALBO	-123 M	-	-0.23 %	$ 916 M	USA
Biophytis SA BPTS	-26.8 M	-	-13.47 %	$ 169 M	France
Aileron Therapeutics ALRN	-65.1 M	-	10.36 %	$ 9.8 M	USA
Midatech Pharma plc MTP	-7 M	-	-18.52 %	$ 27.3 M	Britain
Cabaletta Bio CABA	-172 M	$ 2.82	1.44 %	$ 283 M	USA
Applied Genetic Technologies Corporation AGTC	-17.7 M	-	-	$ 26.5 M	USA
AgeX Therapeutics AGE	-24 M	-	-10.17 %	$ 12.2 K	USA
Aptinyx APTX	-62.6 M	-	-39.0 %	$ 4.57 M	USA
Acorda Therapeutics ACOR	-265 M	-	-24.86 %	$ 820 K	USA
Esperion Therapeutics ESPR	60.3 M	$ 2.85	3.26 %	$ 592 M	USA
Acasti Pharma ACST	-16.7 M	-	4.01 %	$ 150 M	Canada
Equillium EQ	-23.6 M	$ 2.06	-	$ 118 M	USA
Adverum Biotechnologies ADVM	-139 M	-	-	$ 86.2 M	USA
Acer Therapeutics ACER	-24.6 M	-	2.71 %	$ 14 M	USA
Advaxis ADXS	-36.3 M	-	-9.65 %	$ 45.9 M	USA
Ayala Pharmaceuticals AYLA	-37.5 M	-	-	$ 7.46 M	Israel
Avenue Therapeutics ATXI	-11.3 M	-	-52.27 %	$ 4.45 M	USA
Autolus Therapeutics plc AUTL	-241 M	$ 1.29	-3.01 %	$ 329 M	Britain
Stoke Therapeutics STOK	-20.6 M	$ 33.7	-0.27 %	$ 2 B	USA
BeiGene, Ltd. BGNE	447 M	-	0.49 %	$ 251 B	Cayman-islands
bluebird bio BLUE	-244 M	-	-	$ 546 M	USA
Heron Therapeutics HRTX	-2.54 M	$ 0.83	3.62 %	$ 138 M	USA
BioDelivery Sciences International BDSI	37.1 M	-	-4.8 %	$ 255 M	USA
Cara Therapeutics CARA	-121 M	-	-3.03 %	$ 260 M	USA
ChemoCentryx CCXI	-130 M	-	-	$ 3.74 B	USA
Aeglea BioTherapeutics AGLE	-210 M	-	-	$ 1.01 B	USA
Avid Bioservices CDMO	-18.7 M	-	-	$ 789 M	USA
CureVac N.V. CVAC	-412 M	-	-	$ 867 M	Germany
Savara SVRA	-124 M	$ 5.25	-0.57 %	$ 1.17 B	USA
China SXT Pharmaceuticals SXTC	-2.68 M	$ 1.32	-5.2 %	$ 1.88 M	China
Bellerophon Therapeutics BLPH	-22.4 M	-	-74.18 %	$ 955 K	USA
Kala Pharmaceuticals KALA	-41 M	$ 0.2	-6.67 %	$ 759 K	USA
Tarsus Pharmaceuticals TARS	-71 M	$ 67.2	0.36 %	$ 2.81 B	USA
CRISPR Therapeutics AG CRSP	-665 M	$ 47.55	0.98 %	$ 4.28 B	Schweiz
Arbutus Biopharma Corporation ABUS	-38.2 M	$ 4.45	-1.77 %	$ 853 M	Canada
AIkido Pharma AIKI	-11.5 M	-	1.93 %	$ 17.4 M	USA
Allakos ALLK	-196 M	-	-	$ 28.6 M	USA
Brickell Biotech BBI	-6.36 M	-	-5.38 %	$ 6.06 M	USA
Allena Pharmaceuticals ALNA	-47.6 M	-	3.16 %	$ 1.9 M	USA